Remed sales accelerate in 2nd quarter

AFTER a majority stake in its ownership was acquired by MOHS Analytics Inc. in the last quarter of 2024, Remed Pharmaceuticals recorded accelerated sales in the first half of 2025.

ADVANCING PHARMACEUTICALS Remed was founded as a research and development oriented pharmaceutical company. PHOTO FROM REMED

Sales in the first semester grew by 88 percent versus target, and 35 percent growth over the same period in 2024. Growth in the quarter ending June 2024 was even more impressive with 102 percent growth over target and 70 percent increase over the previous year.

Sales at the Mercury Drug chain increased at a remarkable rate, doubling over the same period last year.

Accounting for the growth in sales was the increase in the distribution footprint in major key accounts and national chain drugstores with outlets increasing from 2,500 to 4,000 nationwide, ensuring broader accessibility and visibility.

Remed is focusing on establishing at least 80 percent presence for “Must Carry” brands in Mercury, Watsons, Generika, and other major chain drugstores nationwide. As a result of this focus, five new products with seven SKUs were included at these major drug stores.

A digital platform was also deployed by its medical representatives to drive prescription generation among doctors.

To ensure a continuous flow of products through its development pipeline and expand its product mix, Remed initiated an 8-quarter product planning road map, which is expected to enable Remed to launch new pediatric line extensions and introduce innovative, first-to-market offerings in new therapeutic classes.

MOHS Analytics acquired majority ownership of Remed Pharmaceuticals in pursuit of its strategy of vertical integration of its flagship health care and wellness business. The acquisition is in line with MOHS’s 5-year road map to grow into one of the Philippines’ largest fully integrated health and wellness companies.